Sodium valproate in the treatment of cerebellar disorders.
Because of the high concentrations of gamma-aminobutyric acid (GABA) in the cerebellar cortex and nuclei, an attempt was made to enhance GABAergic transmission in patients with cerebellar disease. Maximum tolerated doses of sodium valproate, a drug which inhibits the degradation of GABA, failed to influence cerebellar deficits in a double blind crossover study on six patients.
D002526:Cerebellar Diseases / Q000188:drug therapy*; D002998:Clonazepam / Q000627:therapeutic use; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D009118:Muscimol / Q000627:therapeutic use; D014635:Valproic Acid / Q000008:administration & dosage / Q000627:therapeutic use*
D009118:Muscimol; D002998:Clonazepam; D014635:Valproic Acid